in the vicinity of King’s Cross, and that around 40 workers will be based at the site from Novo Nordisk’s R&D and IT divisions. The KQ cluster is in close proximity to major institutions at ...

Novo Nordisk has been one of the chief beneficiaries of the boom in GLP-1 drugs, which have shown great promise in fighting obesity. Competition in the space is fierce, but shares got a much ...

Ozempic weight-loss drug maker Novo Nordisk on Wednesday expanded an existing agreement with a drug developer that uses artificial intelligence. Novo Nordisk said an agreement reached last year ...